BioDlink International Co (1875.HK) Stock Price

BioDlink International Co Price

CLOSED
3.45CNY-0.0077 (-0.22 %)
Market closed

Over the last 8 years BioDlink International Co grew revenue by 76.3% annually, reaching 848.41 M CNY. For BioDlink International Co, the net margin of -13.8% is up versus -353.7% a few years ago. The consensus 12-month price target for BioDlink International Co is 2.10 CNY, about 39.1% below where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 133% above its 52-week low.

BioDlink International Co stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of BioDlink International Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how BioDlink International Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing BioDlink International Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

BioDlink International Co Stock Price History
DateBioDlink International Co Price
8/21/20263.45 CNY
8/20/20263.46 CNY
8/19/20263.38 CNY
8/18/20263.53 CNY
8/17/20263.34 CNY
8/14/20263.25 CNY
8/13/20263.29 CNY
8/12/20263.32 CNY
8/11/20263.22 CNY
8/10/20263.29 CNY
8/7/20263.12 CNY
8/6/20262.96 CNY
8/5/20262.99 CNY
8/4/20262.89 CNY
8/3/20262.77 CNY
7/31/20262.76 CNY
7/30/20262.81 CNY
7/29/20262.81 CNY
7/28/20262.89 CNY
7/27/20262.82 CNY
7/24/20262.90 CNY
7/23/20262.96 CNY
7/22/20262.88 CNY
7/21/20262.94 CNY
7/20/20262.87 CNY
7/17/20262.97 CNY
7/16/20263.21 CNY
7/15/20263.21 CNY
7/14/20262.94 CNY
7/13/20262.93 CNY
7/10/20263.12 CNY
7/9/20263.01 CNY
7/8/20263.12 CNY
7/7/20263.17 CNY
7/6/20263.16 CNY
7/3/20263.12 CNY
7/2/20263.03 CNY
6/30/20262.84 CNY
6/29/20262.93 CNY
6/26/20262.78 CNY
6/25/20262.88 CNY
6/24/20262.79 CNY
6/23/20262.79 CNY
6/22/20262.75 CNY
6/18/20262.81 CNY
6/17/20262.84 CNY
6/16/20262.91 CNY
6/15/20263.06 CNY
6/12/20263.13 CNY
6/11/20263.08 CNY
6/10/20262.98 CNY
6/9/20262.91 CNY
6/8/20263.03 CNY
6/5/20263.15 CNY
6/4/20263.25 CNY
6/3/20263.23 CNY
6/2/20263.22 CNY
6/1/20263.12 CNY
5/29/20263.59 CNY
5/28/20263.56 CNY
5/27/20263.66 CNY
5/26/20263.96 CNY
5/22/20263.86 CNY
5/21/20263.84 CNY
5/20/20263.79 CNY
5/19/20263.82 CNY
5/18/20263.93 CNY
5/15/20263.95 CNY
5/14/20263.93 CNY
5/13/20264.07 CNY
5/12/20264.11 CNY
5/11/20264.24 CNY
5/8/20264.31 CNY
5/7/20264.24 CNY
5/6/20264.27 CNY
5/5/20264.30 CNY
5/4/20264.30 CNY
4/30/20264.07 CNY
4/29/20264.23 CNY
4/28/20263.97 CNY
4/27/20263.91 CNY
4/24/20264.00 CNY
4/23/20263.93 CNY
4/22/20264.02 CNY
4/21/20263.97 CNY
4/20/20263.99 CNY
4/17/20264.11 CNY
4/16/20264.24 CNY
4/15/20264.27 CNY
4/14/20264.24 CNY
4/13/20264.17 CNY
4/10/20264.21 CNY
4/9/20264.18 CNY
4/8/20264.32 CNY
4/2/20264.33 CNY
4/1/20264.50 CNY
3/31/20264.46 CNY
3/30/20264.90 CNY
3/27/20264.95 CNY
3/26/20264.55 CNY
3/25/20264.61 CNY
3/24/20264.74 CNY
3/23/20264.40 CNY
3/20/20264.53 CNY
3/19/20264.53 CNY
3/18/20263.89 CNY
3/17/20263.75 CNY
3/16/20263.65 CNY
3/13/20263.76 CNY
3/12/20263.87 CNY
3/11/20263.51 CNY
3/10/20263.51 CNY
3/9/20263.53 CNY
3/6/20263.49 CNY
3/5/20263.49 CNY
3/4/20263.51 CNY
3/3/20263.47 CNY
3/2/20263.51 CNY
2/27/20263.55 CNY
2/26/20263.52 CNY
2/25/20263.62 CNY
2/24/20263.66 CNY
2/23/20263.67 CNY
2/20/20263.65 CNY
2/16/20263.64 CNY
2/13/20263.64 CNY
2/12/20263.64 CNY
2/11/20263.64 CNY
2/10/20263.66 CNY
2/9/20263.64 CNY
2/6/20263.68 CNY
2/5/20263.72 CNY
2/4/20263.59 CNY
2/3/20263.55 CNY
2/2/20263.52 CNY
1/30/20263.57 CNY
1/29/20263.59 CNY
1/28/20263.62 CNY
1/27/20263.63 CNY
1/26/20263.53 CNY
1/23/20263.59 CNY
1/22/20263.56 CNY
1/21/20263.64 CNY
1/20/20263.66 CNY
1/19/20263.69 CNY
1/16/20263.69 CNY
1/15/20263.63 CNY
1/14/20262.17 CNY
1/13/20262.17 CNY
1/12/20262.17 CNY
1/9/20262.17 CNY
1/8/20262.17 CNY
1/7/20262.17 CNY
1/6/20262.17 CNY
1/5/20262.17 CNY
1/2/20262.17 CNY
12/31/20252.17 CNY
12/30/20252.17 CNY
12/29/20252.17 CNY
12/24/20252.17 CNY
12/23/20251.82 CNY
12/22/20251.74 CNY
12/19/20251.76 CNY
12/18/20251.72 CNY
12/17/20251.72 CNY
12/16/20251.68 CNY
12/15/20251.72 CNY
12/12/20251.72 CNY
12/11/20251.65 CNY
12/10/20251.59 CNY
12/9/20251.56 CNY
12/8/20251.48 CNY
12/5/20251.48 CNY
12/4/20251.49 CNY
12/3/20251.48 CNY
12/2/20251.50 CNY
12/1/20251.50 CNY
11/28/20251.54 CNY
11/27/20251.52 CNY
11/26/20251.54 CNY
11/25/20251.54 CNY
11/24/20251.56 CNY
11/21/20251.56 CNY
11/20/20251.61 CNY
11/19/20251.61 CNY
11/18/20251.61 CNY
11/17/20251.64 CNY
11/14/20251.66 CNY
11/13/20251.68 CNY
11/12/20251.76 CNY
11/11/20251.80 CNY
11/10/20251.68 CNY
11/7/20251.62 CNY
11/6/20251.67 CNY
11/5/20251.71 CNY
11/4/20251.65 CNY
11/3/20251.67 CNY
10/31/20251.72 CNY
10/30/20251.72 CNY
10/28/20251.76 CNY
10/27/20251.78 CNY
10/24/20251.72 CNY
10/23/20251.66 CNY
10/22/20251.69 CNY
10/21/20251.75 CNY
10/20/20251.82 CNY
10/17/20251.82 CNY
10/16/20251.86 CNY
10/15/20251.86 CNY
10/14/20251.84 CNY
10/13/20251.88 CNY
10/10/20251.86 CNY
10/9/20251.89 CNY
10/8/20251.97 CNY
10/6/20251.91 CNY
10/3/20251.95 CNY
10/2/20251.94 CNY
9/30/20251.95 CNY
9/29/20251.89 CNY
9/26/20251.98 CNY
9/25/20251.96 CNY
9/24/20251.97 CNY
9/23/20251.98 CNY
9/22/20252.04 CNY
9/19/20251.90 CNY
9/18/20251.91 CNY
9/17/20251.80 CNY
9/16/20251.95 CNY
9/15/20252.03 CNY
9/12/20252.04 CNY
9/11/20251.95 CNY
9/10/20252.04 CNY
9/9/20252.08 CNY
9/8/20252.16 CNY
9/5/20252.10 CNY
9/4/20251.88 CNY
9/3/20251.99 CNY
9/2/20251.84 CNY
9/1/20251.91 CNY
8/29/20251.91 CNY
8/28/20251.85 CNY
8/27/20251.92 CNY
Access this data via the Eulerpool API
Get Free API Key

BioDlink International Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
86.04 M CNY
-302.55 M CNY
-304.30 M CNY
Jan 1, 2022
426.87 M CNY
-45.71 M CNY
-49.92 M CNY
Jan 1, 2023
773.73 M CNY
-35.56 M CNY
-37.76 M CNY
Jan 1, 2024
1.09 B CNY
41.25 M CNY
34.76 M CNY
Jan 1, 2025
848.41 M CNY
-105.65 M CNY
-116.92 M CNY
Jan 1, 2026 (e)
592.56 M CNY
-142.88 M CNY
7.59 M CNY
Jan 1, 2027 (e)
684.78 M CNY
-165.12 M CNY
53.90 M CNY
Jan 1, 2028 (e)
839.70 M CNY
-202.47 M CNY
69.08 M CNY

BioDlink International Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 10:17 AM
 
REVENUEB CNY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM CNY
EBITM CNY
EBIT MARGIN%
NET INCOMEM CNY
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e
0.050.040.050.020.090.440.781.100.870.590.680.84
–-23.5315.38-51.11300.00402.2776.4740.77-20.77-31.9515.5422.66
92.1684.6273.3368.1836.3683.7173.4671.2252.0752.0752.0752.07
47.0033.0033.0015.0032.00370.00573.00782.00453.00308.25356.15436.86
-105.00-237.00-298.00-288.00-302.00-45.00-35.0041.00-105.00-142.00-165.00-202.00
-205.88-607.69-662.22-1,309.09-343.18-10.18-4.493.73-12.07-23.99-24.12-24.08
-148.00-268.00-299.00-288.00-304.00-49.00-37.0034.00-116.007.0053.0069.00
–81.0811.57-3.685.56-83.88-24.49-191.89-441.18-106.03657.1430.19
570.00570.00570.00570.67575.23703.42725.20725.20725.20725.20725.20725.20
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales BioDlink International Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue BioDlink International Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare BioDlink International Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares BioDlink International Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against BioDlink International Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

BioDlink International Co stock margins

The BioDlink International Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioDlink International Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioDlink International Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
37.20 %
-351.65 %
-353.68 %
Jan 1, 2022
86.82 %
-10.71 %
-11.69 %
Jan 1, 2023
74.18 %
-4.60 %
-4.88 %
Jan 1, 2024
72.09 %
3.80 %
3.20 %
Jan 1, 2025
53.41 %
-12.45 %
-13.78 %
Jan 1, 2026 (e)
53.41 %
-24.11 %
1.28 %
Jan 1, 2027 (e)
53.41 %
-24.11 %
7.87 %
Jan 1, 2028 (e)
53.41 %
-24.11 %
8.23 %

BioDlink International Co Stock Revenue, EBIT, Earnings per Share

The BioDlink International Co earnings per share therefore indicates how much revenue BioDlink International Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.15 CNY
-0.53 CNY
-0.53 CNY
Jan 1, 2022
0.61 CNY
-0.06 CNY
-0.07 CNY
Jan 1, 2023
1.07 CNY
-0.05 CNY
-0.05 CNY
Jan 1, 2024
1.50 CNY
0.06 CNY
0.05 CNY
Jan 1, 2025
1.17 CNY
-0.15 CNY
-0.16 CNY
Jan 1, 2026 (e)
0.82 CNY
-0.20 CNY
0.01 CNY
Jan 1, 2027 (e)
0.94 CNY
-0.23 CNY
0.07 CNY
Jan 1, 2028 (e)
1.16 CNY
-0.28 CNY
0.10 CNY

BioDlink International Co business model & stock analysis

TOT BIOPHARM International Co Ltd is a global biotechnology company based in Hong Kong. It was founded in 2005 and has since become a major player in the biopharmaceutical industry. The company's goal is to contribute to the improvement of medical care through innovative research and development of biological drugs. TOT BIOPHARM's business activities include pharmaceutical development, clinical research, and production of biological drugs. It serves various sectors, including cancer, immunology, ophthalmology, and vaccines. TOT BIOPHARM is strongly committed to the development of biopharmaceuticals and aims to be a leader in this field. One important focus of TOT BIOPHARM is the research of cancer drugs. The company has several drugs in its oncology pipeline, including a treatment for lung cancer called "Ponatinib". Additionally, TOT BIOPHARM has introduced a range of immuno-oncology therapies that can be used to treat various types of cancer. In the field of immunology, TOT BIOPHARM has launched several drugs for the treatment of autoimmune diseases, including "Natalizumab" for multiple sclerosis. Another important immunotherapy developed by TOT BIOPHARM is "Eculizumab," which is used to treat two rare blood disorders. In ophthalmology, TOT BIOPHARM is developing a new drug for the treatment of wet age-related macular degeneration (AMD). The drug is being tested in a Phase III clinical trial and has the potential to become the first biopharmaceutical for the treatment of AMD. Furthermore, TOT BIOPHARM has also developed vaccines, including a vaccine against the Japanese encephalitis virus (JEV) and a vaccine against enterovirus 71 (EV71). Both vaccines have been approved in China and are in high demand. TOT BIOPHARM's business model focuses on building a pipeline of innovative biopharmaceuticals that meet the needs of patients. The company operates a comprehensive research and development infrastructure that helps discover and develop new drug candidates. TOT BIOPHARM collaborates with universities, government agencies, and other business partners to accelerate its research and development and strengthen its market position. In addition, TOT BIOPHARM has a strong presence in the Chinese market for biopharmaceuticals. The company has a state-approved clinical research facility with over 1,000 employees in China and collaborates with leading Chinese hospitals and specialty clinics. This has given TOT BIOPHARM a preferred position in the Chinese market for biopharmaceuticals, and the company aims to expand its presence in other markets worldwide. Overall, TOT BIOPHARM International Co Ltd has built an impressive portfolio of biopharmaceuticals in recent years and is expected to continue to play a significant role in the biopharmaceutical industry. With a clear focus on research and development and a growing market position in China and other countries, the company is well-positioned to expand its business activities and strengthen its presence in the global market.

BioDlink International Co SWOT Analysis

Strengths

TOT BIOPHARM International Co Ltd has several key strengths that contribute to its success in the pharmaceutical industry. These strengths include:

  • Strong Research and Development Capabilities: TOT BIOPHARM has a dedicated R&D team that consistently develops innovative and high-quality pharmaceutical products.
  • Advanced Manufacturing Facilities: The company possesses state-of-the-art manufacturing facilities that ensure efficient production processes and high product quality.
  • Extensive Product Portfolio: TOT BIOPHARM offers a wide range of pharmaceutical products, catering to various medical needs and therapeutic areas.
  • Established Market Presence: The company has established a strong market presence in both domestic and international markets, building trust and loyalty among customers.

Weaknesses

There are certain weaknesses that TOT BIOPHARM International Co Ltd should address to maintain its competitive edge:

  • Dependency on Limited Product Lines: Although TOT BIOPHARM has an extensive product portfolio, the company's revenue heavily relies on a few key products, making it vulnerable to market fluctuations.
  • Inconsistent Supply Chain: The company sometimes faces challenges in maintaining a consistent and reliable supply chain, leading to potential delays in product availability.
  • Limited International Presence: TOT BIOPHARM's international market reach is relatively limited compared to some of its competitors, hindering its potential for further growth.

Opportunities

There are several opportunities that TOT BIOPHARM International Co Ltd can explore to expand its market share and enhance its competitiveness:

  • Increasing Demand for Biopharmaceuticals: With the growing trend towards personalized medicine and advancements in biotechnology, there is an increasing demand for biopharmaceutical products, presenting a significant opportunity for TOT BIOPHARM to further expand its product offerings.
  • Expansion into Emerging Markets: TOT BIOPHARM can focus on expanding its presence in emerging markets, where there is a rising demand for quality pharmaceutical products and less intense competition.
  • Inorganic Growth through Strategic Partnerships: The company can consider strategic partnerships or acquisitions to access new technologies, increase market reach, and diversify its product portfolio.

Threats

TOT BIOPHARM International Co Ltd should be wary of the following threats that may impact its business:

  • Intense Competition: The pharmaceutical industry is highly competitive, with both domestic and international players vying for market share. TOT BIOPHARM needs to continuously innovate and differentiate its products to stay ahead.
  • Stringent Regulatory Environment: Compliance with strict regulations and requirements imposed by regulatory bodies can pose challenges for TOT BIOPHARM, potentially delaying the approval process for new products.
  • Economic Volatility: Global economic fluctuations and uncertainties can impact consumer spending on healthcare products, affecting TOT BIOPHARM's sales and revenue.

BioDlink International Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

BioDlink International Co historical P/E ratio, EBIT multiple, and P/S ratio

BioDlink International Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

BioDlink International Co shares outstanding

The number of shares of BioDlink International Co was 725.2 M in 2025. This indicates how many shares BioDlink International Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
575.23 M Stocks
Jan 1, 2022
703.42 M Stocks
Jan 1, 2023
725.20 M Stocks
Jan 1, 2024
725.20 M Stocks
Jan 1, 2025
725.20 M Stocks
Jan 1, 2026 (e)
725.20 M Stocks
Jan 1, 2027 (e)
725.20 M Stocks
Jan 1, 2028 (e)
725.20 M Stocks

Current BioDlink International Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
2.10
Last Price
3.41
Currency
CNY
12M Return Potential
-38.24 %
LTM Return
0 %

BioDlink International Co shareholder structure

% Name
30.26695%
Vivo Capital, LLC
Vivo Capital, LLC
29.41431%
Center Laboratories Inc
Center Laboratories Inc
7.80112%
Chengwei Evergreen Capital, L.P.
Chengwei Evergreen Capital, L.P.
6.77565%
Advantech Capital II L.P.
Advantech Capital II L.P.
0.75368%
Yeh Huang (Chun Ying)
Yeh Huang (Chun Ying)

BioDlink International Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
42.5%
Float Shares
-
Shares Outstanding
-

BioDlink International Co Executives and Management Board

14 members · avg. age 52 · 36 % women

JL

Dr. Jun Liu (54)

Chief Executive Officer, Chief Scientific Officer, Executive Director · since 2018

3.44 M CNY

Management

CH

Ms. Chun- Ying Yeh- Huang (63)

Non-Executive Vice Chairman of the Board · since 2016

3.18 M CNY
WL

Mr. Wing Yat Lui

Joint Company Secretary

–
YC

Ms. Yan Chen

Investor Relations · since 2022

–

Board of Directors

SF

Mr. Shan Fu (54)

Non-Executive Chairman of the Board

–
QD

Dr. Qing Duan (39)

Senior Director of the New Drug Development

–
SF

Ms. Shan Feng (43)

Senior Director of the Regulatory Affairs Department

–
CW

Mr. Chih- Yuan Wu (49)

Senior Director of the Strategy and Business Development

–
BX

Ms. Ben Xiao (41)

Senior Finance Director

–
YC

Mr. Yifan Chen (42)

Joint Company Secretary, Senior Director of the Legal Division

–

BioDlink International Co Supply Chain

BioDlink International Co Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
1 companies
#NameTrend
1
Zhaoke Ophthalmology
Supplier·Customer·Pharmaceuticals·CN
0.73
0.61
0.51
0.89
0.80
—

Frequently asked questions about BioDlink International Co

The business model of TOT BIOPHARM International Co Ltd is centered around the development, production, and commercialization of innovative biopharmaceutical products. With a focus on oncology and autoimmune diseases, TOT BIOPHARM utilizes advanced technologies and international collaborations to discover novel therapies. By integrating research, manufacturing, sales, and marketing, the company aims to deliver high-quality and cost-effective medicines to patients worldwide. As a leading biopharmaceutical company, TOT BIOPHARM is committed to improving healthcare outcomes and contributing to the advancement of medical science.

TOT BIOPHARM International Co Ltd is primarily active in the pharmaceutical industry.

Some of the main competitors of TOT BIOPHARM International Co Ltd in the market include large pharmaceutical companies such as Johnson & Johnson, Pfizer, Novartis, and Roche. These companies also operate in the biopharmaceutical sector and offer a wide range of innovative drugs and therapies similar to TOT BIOPHARM.

TOT BIOPHARM International Co Ltd is a leading global biopharmaceutical company that focuses on the development and commercialization of innovative therapies. Established in (year), TOT BIOPHARM has made significant contributions to the fields of (specific areas). With a strong commitment to research and development, the company has successfully launched several breakthrough drugs, including (drug names). TOT BIOPHARM's exemplary track record of delivering effective treatments has earned them a reputable position in the pharmaceutical industry. With a dedicated team of experts and state-of-the-art facilities, TOT BIOPHARM continues to strive for excellence in improving patient outcomes and revolutionizing healthcare worldwide.

TOT BIOPHARM International Co Ltd has achieved several significant milestones in its journey. The company has demonstrated its commitment to innovation and research in the biopharmaceutical industry. One of the noteworthy accomplishments includes the successful development and commercialization of groundbreaking medicines that have positively impacted patient lives globally. TOT BIOPHARM International Co Ltd has also established strategic partnerships with leading healthcare organizations, enabling the company to expand its reach and further contribute to the advancement of healthcare worldwide. Additionally, the company has achieved remarkable growth and recognition, solidifying its position as a prominent player in the biopharmaceutical market. TOT BIOPHARM International Co Ltd continues to strive towards excellence in delivering innovative solutions for improving global healthcare.

TOT BIOPHARM International Co Ltd is primarily present in China, as it is a Chinese biopharmaceutical company. The company is focused on the research, development, and commercialization of innovative therapeutics for oncology and other diseases. With its headquarters in Suzhou, TOT BIOPHARM operates across various provinces in China, including Shanghai, Beijing, Guangdong, and Jiangsu. As a leading player in the Chinese biopharmaceutical industry, TOT BIOPHARM aims to expand its presence both domestically and internationally, contributing to the advancement of healthcare and the treatment options available to patients worldwide.

TOT BIOPHARM International Co Ltd is a renowned pharmaceutical company that is committed to delivering innovative treatments and improving global health. The company values integrity, excellence, and collaboration in all aspects of its operations. TOT BIOPHARM upholds a corporate philosophy focused on customer satisfaction, quality assurance, and social responsibility. By adopting cutting-edge technology and stringent quality control measures, the company consistently produces high-quality pharmaceutical products. TOT BIOPHARM's dedication to research and development demonstrates its persistent drive to provide breakthrough solutions in the healthcare industry. With a strong emphasis on patient well-being and ethical conduct, TOT BIOPHARM International Co Ltd is a trusted leader in the pharmaceutical sector.

Analysts currently set an average price target of 2.10 CNY for the BioDlink International Co stock (median: 2.10 CNY), implying -38.2 % versus the latest price. The consensus is based on 7 analyst ratings.

BioDlink International Co Analyst Price Targets 2026

7 analysts currently rate the BioDlink International Co stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect BioDlink International Co to generate revenue of 592.56 M CNY and earnings per share of 0.01 CNY.

BioDlink International Co Analyst Price Targets 2026

Converted at the current exchange rate, the BioDlink International Co share trades at 0.44 EUR (3.45 CNY).

TOT BIOPHARM International Co Ltd is a biopharmaceutical company that was founded in 2000 and is headquartered in Beijing, China. The company is engaged in the research, development, manufacturing, and marketing of innovative drugs for the treatment of cancer and other serious diseases. The business model of TOT BIOPHARM is based on three divisions: research and development, manufacturing, and marketing of drugs. In the research and development department, scientists work to develop new drugs and improve existing ones. The company has a strong research infrastructure that allows it to implement the latest discoveries in cancer research. Drug manufacturing is another important division. TOT BIOPHARM has a 40,000-square-meter production facility in Beijing where state-of-the-art technologies are used to produce high-quality and safe drugs. The company has comprehensive quality assurance and control systems to ensure the purity, efficacy, and safety of the drugs. The marketing of drugs is the third pillar of TOT BIOPHARM's business model. The company has a wide distribution network in China and is working to expand its reach to global markets. It has formed partnerships with leading pharmaceutical companies worldwide to market its drugs internationally. TOT BIOPHARM offers a wide range of drugs for the treatment of cancer and other serious diseases. The key products include: 1. Yiviva: An innovative drug for the treatment of breast cancer, based on the blocking effect of progesterone receptors. 2. Disitamab vedotin: An antibody-drug conjugate for the treatment of cancer, currently in phase III clinical trials. 3. TAA401: An immunotherapy developed by TOT BIOPHARM for the treatment of advanced stage liver cancer. 4. TP-0903: A tyrosine kinase inhibitor specifically designed for the treatment of central nervous system tumors. 5. ABBV-157: A drug developed in collaboration with AbbVie Inc., currently in phase III clinical trial for the treatment of pancreatic cancer. Overall, TOT BIOPHARM focuses on the research, development, and marketing of innovative drugs for the treatment of cancer and other serious diseases. Through a strong research infrastructure, state-of-the-art production facilities, and a wide distribution network, the company has been able to expand its reach to global markets while maintaining a focus on the quality and safety of its drugs.

The expected revenue of BioDlink International Co is 592.56 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BioDlink International Co is 7.59 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BioDlink International Co is currently 329.93. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BioDlink International Co stock.

The price-to-sales ratio (P/S) of BioDlink International Co is currently 4.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BioDlink International Co stock.

The Eulerpool Quality Score for BioDlink International Co is 2/10.

The ISIN of BioDlink International Co is HK0000545266. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of BioDlink International Co is 1875.HK. The ticker symbol is used to trade BioDlink International Co shares on the stock exchange.

BioDlink International Co paid dividends every year for the past 0 years.

BioDlink International Co is assigned to the 'Health' sector.

The dividends of BioDlink International Co are distributed in CNY.

All fundamentals and in-depth analysis of BioDlink International Co

Our stock analysis for BioDlink International Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioDlink International Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

BioDlink International Co Stock
BioDlink International Co Revenue→
BioDlink International Co Stock
BioDlink International Co Net Income→
BioDlink International Co Stock
BioDlink International Co P/E→
BioDlink International Co Stock
BioDlink International Co P/S→
BioDlink International Co Stock
BioDlink International Co EBIT→
BioDlink International Co Stock
BioDlink International Co Dividend→
BioDlink International Co Stock
BioDlink International Co Directors Dealings→
BioDlink International Co Stock
BioDlink International Co Stocks→
BioDlink International Co Stock
BioDlink International Co Market capitalization→
BioDlink International Co Stock
BioDlink International Co Debt→
BioDlink International Co Stock
BioDlink International Co Liabilities→
BioDlink International Co Stock
BioDlink International Co Equity→
BioDlink International Co Stock
BioDlink International Co AAQS→
BioDlink International Co Stock
BioDlink International Co Employees→
BioDlink International Co Stock
BioDlink International Co ROE→
BioDlink International Co Stock
BioDlink International Co ROA→
BioDlink International Co Stock
BioDlink International Co ROCE→
BioDlink International Co Stock
BioDlink International Co News→
BioDlink International Co Stock
BioDlink International Co Analyst Price Targets→

Health Stocks

Biodyne CoBiodexa PharmaceticalsBiofil Chemicals and PharmaceuticalsBiodesixBiofronteraBiocytogen Pharmaceuticals (Beijing) CoBiofronteraBiocure TechnologyBiogaiaBioCryst PharmaceuticalsBiogenBioCorRxAll Stocks A–Z →